EMA Set To Adopt Safe-Use Recommendations For Anti-Epilepsy Drug Valproate
Executive Summary
The European Medicines Agency is scheduled to adopt final recommendations for improving the safety of the anti-epileptic drug valproate – the subject of the agency’s very first public hearing.
You may also be interested in...
EMA Probe Into Paternal Valproate Exposure Risk Continues After ‘Errors’ Found In Study
Initial results from a study indicate that children born to men taking valproate medicines are at an increased risk of having neurodevelopmental disorders, but “important limitations” and “errors” with the data highlight the need for further analysis.
EMA Calls For Visual Warnings Among Measures To Restrict Valproate Use
The European Medicines Agency has recommended that EU member states should introduce further restrictions on the use of valproate-containing medicines to avoid the drug's exposure in pregnancy.
EMA Urged To Do Better On Valproate Risk Reduction In Pregnant Women
There were passionate testimonies from patients affected by Sanofi’s anti-epileptic drug valproate at the European Medicines Agency's first public hearing on medicines safety. There was almost full agreement among those who testified that existing risk reduction measures are not working.